Core Viewpoint - The company announced the presentation of clinical data for its core product, Tienogratinib, as a monotherapy for patients with advanced cholangiocarcinoma (CCA) at the 2026 American Society of Clinical Oncology Gastrointestinal Cancers Symposium (ASCO GI) [1] Group 1 - The clinical data was presented in a poster format, indicating a significant step in the company's research and development efforts [1]